This research study presents the development of monoclonal antibodies (mAbs) targeting ST3Gal-I, a key enzyme involved in cancer-associated glycosylation. Recombinant ST3Gal-I protein was successfully expressed and purified, followed by the generation of highly specific antibodies using hybridoma technology.

The developed mAbs demonstrated strong specificity and sensitivity in detecting ST3Gal-I expression, particularly in breast cancer tissue samples, with minimal background in benign tissues. These antibodies were validated using techniques such as ELISA, Western blotting, and immunohistochemistry, confirming their reliability.

These findings highlight the potential of ST3Gal-I targeted monoclonal antibodies as a valuable tool for cancer detection and glycan research. The study opens new avenues for developing advanced diagnostic solutions and improving cancer biomarker identification.